ArticleJournal of ovarian research2026
LINC00467 mediates PARP inhibitor resistance in high-grade serous ovarian cancer by regulating miR-485-5p/RAD50 axis.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeHigh-grade serous ovarian cancer (HGSOC) is extremely lethal owing to its high risk of recurrence and resistance to common chemotherapy. PARP inhibitor (PARPi) is currently the most promising target drug among patients with HGSOC, but its resistance mechanism remains unclear. In this study, we aimed to investigate the mechanism of PARPi resistance and explore new therapeutic targets.
methodsWe established olaparib-acquired resistant cell lines denoted SKOV3-OR and performed lncRNA sequencing. Biological behavior study illustrated the effect of LINC00467 on HGSOC cells in vitro and vivo. Bioinformatics and the dual-luciferase reporter system confirmed the downstream target genes. Patient-derived xenograft (PDX) models were established to validate the effect of LINC00467 on response to olaparib.
resultsLncRNA sequencing revealed that LINC00467 was upregulated in PARPi resistant HGSOC cell and predicted poor prognosis. Biological behavior study comfirmed LINC00467 promoted cell proliferation, metastasis and PARPi resistance in HGSOC. Furthermore, the dual-luciferase reporter system confirmed its function as a competitive endogenous RNA by directly sponging miR-485-5p, which further regulated its target, RAD50. Additionally, LINC00467 ASO played a synergistic role with olaparib in HGSOC PDX models.
conclusionOur results showed that LINC00467 could confer PARPi resistance in HGSOC by regulating the miR-485-5p/RAD50 axis and provide a novel therapeutic target in PARPi synergistic treatment for HGSOC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.